TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26548726

Group type: EXPERIMENTAL
Intervention: AverTeaX applied topically six to eight times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle (100% glycerin USP)
Number of subjects: 40
Study: 22976217

Group type: EXPERIMENTAL
Intervention: Betaine (1.25 g BID)
Number of subjects: 12
Study: 22065532

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19636326

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17013640

Group type: EXPERIMENTAL
Intervention: Priming drink (0.03 g/dl alcohol)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Taste-masked placebo
Number of subjects: 16
Study: 14760122

Group type: EXPERIMENTAL
Intervention: COPP/ABV/IMEP (CAI)
Number of subjects: 588

Group type: COMPARATOR
Intervention: COPP/ABVD (CA)
Number of subjects: 588
Study: 11258039

Group type: EXPERIMENTAL
Intervention: Onion-olive oil maceration product (4 capsules daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (4 capsules daily)
Number of subjects: 24
Study: 9290856

Group type: EXPERIMENTAL
Intervention: Negative outcome task
Number of subjects: 55

Group type: COMPARATOR
Intervention: Neutral outcome control task
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Eating (after negative outcome task)
Number of subjects: 55
Study: 29266863

Group type: EXPERIMENTAL
Intervention: Nebulized hypertonic saline (3% HS) with 2.5 mg salbutamol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nebulized normal saline (NS) with 2.5 mg salbutamol
Number of subjects: 47
Study: 27439433

Group type: EXPERIMENTAL
Intervention: Metformin 2 g (1 g twice daily) plus lifestyle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lifestyle alone
Number of subjects: 60
Study: 24760745

Group type: EXPERIMENTAL
Intervention: Nordic pole walking (NPW+)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nordic pole walking (NPW-)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard home exercise programme (HEP)
Number of subjects: 52
Study: 22427815

Group type: EXPERIMENTAL
Intervention: SVM1 model integrating the expression of 7 molecular biomarkers
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: SVM2 model grouping the expression level of 12 molecular biomarkers and 3 EBV‐related serological biomarkers
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: SVM3 model constructed by combination of SVM1 and SVM2
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cox multivariate regression analysis
Number of subjects: 97
Study: 19625372

Group type: EXPERIMENTAL
Intervention: Intensive intervention targeting LDL-cholesterol <100 mg/dl, using antiplatelet therapy, and switching protease inhibitor therapy.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard intervention aiming for LDL-cholesterol <130 mg/dL.
Number of subjects: 68
Study: 16413333

Group type: EXPERIMENTAL
Intervention: Prostat/Poltit
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14993579

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (0.1 to 0.2 mL subcutaneously injected just before PIV insertion)
Number of subjects: 69

Group type: COMPARATOR
Intervention: ELA-Max (applied to the skin and occluded with Tegaderm 30 minutes before PIV insertion)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nurse ratings of technical difficulty and satisfaction with local anesthesia
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Number of PIV-insertion attempts
Number of subjects: 69
Study: 11237931

Group type: EXPERIMENTAL
Intervention: HFLC diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: LFHC diet
Number of subjects: 6
Study: 9786562

Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma (NTG) eyes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal eyes (control)
Number of subjects: 27
Study: 7837398

Group type: EXPERIMENTAL
Intervention: 10 mg orally
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20 mg orally
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5 mg intramuscularly
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam (all groups)
Number of subjects: 90
Study: 3349552

Group type: EXPERIMENTAL
Intervention: Jackson-Rees system (n = 11)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Paediatric circle absorber system (n = 15)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Jackson-Rees system
Number of subjects: 26

Group type: COMPARATOR
Intervention: Paediatric circle absorber system
Number of subjects: 26
Study: 31769331

Group type: EXPERIMENTAL
Intervention: Tilting group (standing on a tilting board)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (voluntarily leaning forward)
Number of subjects: 20
Study: 31504831

Group type: EXPERIMENTAL
Intervention: Verbal instruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Written handout
Number of subjects: 60
Study: 31260166

Group type: EXPERIMENTAL
Intervention: Interpositional block graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Onlay graft
Number of subjects: 20
Study: 28470507

Group type: EXPERIMENTAL
Intervention: Exercise program (12-week post-radiation)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 59
Study: 26179223

Group type: EXPERIMENTAL
Intervention: Preoperative self‐perceived risk of addiction
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Higher anxiety sensitivity
Number of subjects: 107
Study: 23611404

Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Cisplatin-gemcitabine
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Cisplatin-docetaxel
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Histology subtypes (SCC, AC, LCC, O/NOS)
Number of subjects: 1139
Study: 21321633

Group type: EXPERIMENTAL
Intervention: Desensitizing toothpaste containing 5.53% potassium citrate
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control toothpaste containing 0.76% sodium monofluorophosphate
Number of subjects: 67
Study: 18505216

Group type: EXPERIMENTAL
Intervention: Soft-Start (SS) technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plasma Arc Curing (PAC) technique
Number of subjects: 20
Study: 17191188

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PDT and intravitreal triamcinolone acetonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: PDT with verteporfin
Number of subjects: 0
Study: 14687246

Group type: EXPERIMENTAL
Intervention: Parathyroid surgery
Number of subjects: 3213

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 3213
Study: 11398072

Group type: EXPERIMENTAL
Intervention: 3.0 mg of IL‐4R
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 9258715

Group type: EXPERIMENTAL
Intervention: Mandibular overdenture supported by two implants with ball attachments
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Two implants with an interconnecting bar
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Four interconnected implants
Number of subjects: 110
Study: 8278211

Group type: EXPERIMENTAL
Intervention: Pain events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain event memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensity and sensory quality of pain
Number of subjects: 0
Study: 3434167

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 2

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 2

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 2
Study: 30913381

Group type: EXPERIMENTAL
Intervention: Nylon-flocked (NF) swab cytology
Number of subjects: 326

Group type: COMPARATOR
Intervention: Dacron swab cytology
Number of subjects: 326
Study: 28612375

Group type: EXPERIMENTAL
Intervention: ABVE chemotherapy and 25.5 Gy of involved field radiotherapy for low-risk HL (P9426)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: ABVE-PC chemotherapy and 21 Gy of involved region radiotherapy for intermediate and high-risk HL (P9425)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Comparison of EFS between children and AYA
Number of subjects: 471
Study: 25434365

Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg) administered 30 min prior to surgery and every 12 h for 60 h
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (control group) administered at corresponding time points
Number of subjects: 80
Study: 23835245

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day
Number of subjects: 702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study: 21592110

Group type: EXPERIMENTAL
Intervention: Deferasirox (Exjade), average dose 19.4 ± 6.3 mg/kg per day
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Deferasirox (Exjade)
Number of subjects: 185
Study: 19116326

Group type: EXPERIMENTAL
Intervention: Higher α-tocopherol concentrations (highest compared with lowest quintile)
Number of subjects: 29092

Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat intake (>9.9 g/d) with higher α-tocopherol concentrations
Number of subjects: 29092

Group type: COMPARATOR
Intervention: Dietary tocopherols and tocotrienols
Number of subjects: 29092
Study: 16713013

Group type: EXPERIMENTAL
Intervention: Paclitaxel, etoposide, and carboplatin (TEC) regimen
Number of subjects: 614

Group type: COMPARATOR
Intervention: Carboplatin, etoposide phosphate, and vincristine (CEV) regimen
Number of subjects: 614
Study: 14717835

Group type: EXPERIMENTAL
Intervention: Mimicry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-mimicry (Control)
Number of subjects: 0
Study: 11696142

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 55

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 55
Study: 9246969

Group type: EXPERIMENTAL
Intervention: fosfomycin
Number of subjects: 11

Group type: COMPARATOR
Intervention: CAPF chemotherapy alone (control)
Number of subjects: 11
Study: 7970444

Group type: EXPERIMENTAL
Intervention: 99Tcm‐N,N'‐ethylene‐1‐dicysteine (99Tcm‐EC) complex
Number of subjects: 0
Study: 3296254

Group type: EXPERIMENTAL
Intervention: Latamoxef sodium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 40
Study: 31704159

Group type: EXPERIMENTAL
Intervention: Practice facilitation strategies for preventive cardiovascular care
Number of subjects: 107

Group type: COMPARATOR
Intervention: EHRs that were unable to consistently produce rolling 12-month measures
Number of subjects: 107
Study: 30823460

Group type: EXPERIMENTAL
Intervention: FRED Exergame with biofeedback supervision
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FRED Exergame
Number of subjects: 40
Study: 29258541

Group type: EXPERIMENTAL
Intervention: Intravenous iron polymaltose (single dose calculated using the Ganzoni formula)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Blood transfusion
Number of subjects: 100
Study: 25683075

Group type: EXPERIMENTAL
Intervention: Internet-based treatment programme (n = 124)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Postal treatment programme (n = 126)
Number of subjects: 250
Study: 26265274

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 900
Study: 21560159

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 2388

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 2388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2388
Study: 19778672

Group type: EXPERIMENTAL
Intervention: Heparin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 13819

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 13819

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 13819
Study: 17691578

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation (Acup+ Rehab)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Rehabilitation (Rehab)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (medication, manicol/beronald, Ca2+ antagonist, citicoline, etc.)
Number of subjects: 56
Study: 15338488

Group type: EXPERIMENTAL
Intervention: COBRA therapy (prednisolone, methotrexate, and sulfasalazine)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: COBRA therapy
Number of subjects: 155
Study: 11919306

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg subcutaneously daily for 6 to 10 days followed by enoxaparin for another 21 days)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo (after initial enoxaparin treatment)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study: 9613539

Group type: EXPERIMENTAL
Intervention: Single-hole 27-gauge pencil-point needle
Number of subjects: 50

Group type: COMPARATOR
Intervention: Double-hole 26-gauge pencil-point needle
Number of subjects: 50
Study: 8087360

Group type: EXPERIMENTAL
Intervention: Thiorphan (1.25 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2697584

Group type: COMPARATOR
Intervention: Melphalan and prednisone (MP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Various drug combinations
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Drug combinations
Number of subjects: 13

Group type: COMPARATOR
Intervention: Melphalan alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of adriamycin, carmustine, cyclophosphamide, and melphalan
Number of subjects: 13
Study: 794997

Group type: EXPERIMENTAL
Intervention: Acupuncture (manual)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acupuncture (electrical)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Electrical stimulation with surface electrodes over acupuncture points
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no acupuncture)
Number of subjects: 33
Study: 31642145

Group type: EXPERIMENTAL
Intervention: Elastic and inelastic compression systems
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: NSAID use
Number of subjects: 45
Study: 30243503

Group type: EXPERIMENTAL
Intervention: PS-enriched beverage (2 g PS/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo beverage (without PS)
Number of subjects: 40
Study: 28738295

Group type: EXPERIMENTAL
Intervention: One-day simulation-based team training in obstetrics (12 units)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No team training (12 units)
Number of subjects: 24
Study: 25323140

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Medication (nortriptyline v. venlafaxine)
Number of subjects: 128
Study: 24136634

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 256

Group type: COMPARATOR
Intervention: Conventional self monitoring (Control)
Number of subjects: 256
Study: 21654506

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CMH) 200 mg/kg daily for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19536164

Group type: EXPERIMENTAL
Intervention: Nutritional intervention offered as an adjunct to smoking cessation programmes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritional intervention
Number of subjects: 0
Study: 16762752

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM)
Number of subjects: 88
Study: 15310008

Group type: EXPERIMENTAL
Intervention: Dot-ELISA using PPF antigen
Number of subjects: 261

Group type: COMPARATOR
Intervention: Micro-ELISA
Number of subjects: 261
Study: 11429023

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 32
Study: 9121996

Group type: EXPERIMENTAL
Intervention: 6/6 ms waveform
Number of subjects: 31

Group type: COMPARATOR
Intervention: 3/3 ms waveform
Number of subjects: 31
Study: 8229908

Group type: EXPERIMENTAL
Intervention: Sodium loading (10 g/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 18
Study: 3729085

Group type: EXPERIMENTAL
Intervention: Enflurane (0.4%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (without enflurane)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 30236776

Group type: EXPERIMENTAL
Intervention: Targeted intervention (TP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored counseling and navigation (TCN) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 26290275

Group type: EXPERIMENTAL
Intervention: Atenolol (n=26)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Enalapril (n=25)
Number of subjects: 51
Study: 24102822

Group type: EXPERIMENTAL
Intervention: Health Belief Model-based nursing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 0
Study: 21224376

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg BID daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: DCE-MRI measurements (K(ep))
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cytokine analysis for bFGF
Number of subjects: 37
Study: 16199916

Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium channel blockers
Number of subjects: 0
Study: 11980131

Group type: EXPERIMENTAL
Intervention: Allicor 600 mg/day
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Allicor 2400 mg/day
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Kwai 900 mg/day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 9481530

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg elemental zinc in syrup daily for 12 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (syrup only)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 61
Study: 7616798

Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms twice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 2096042

Group type: EXPERIMENTAL
Intervention: Mechanical anastomosis
Number of subjects: 140

Group type: COMPARATOR
Intervention: Manual anastomosis
Number of subjects: 140

Group type: COMPARATOR
Intervention: Terminolateral anastomosis with separate stitches
Number of subjects: 140
Study: 25830

Group type: EXPERIMENTAL
Intervention: 180 ml 100 proof vodka
Number of subjects: 12

Group type: COMPARATOR
Intervention: 180 ml water
Number of subjects: 12
Study: 29480139

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 0
Study: 27912934

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment administered twice daily for 7-21 days, followed by TCM for AECOPD risk window over 28 days.
Number of subjects: 364

Group type: COMPARATOR
Intervention: Conventional treatment administered according to the assigned group.
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: TCM treatment
Number of subjects: 364

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 364

Group type: COMPARATOR
Intervention: Both TCM and conventional treatments
Number of subjects: 364
Study: 26241543

Group type: EXPERIMENTAL
Intervention: Mucosolvan (90 mg/day aerosol + 180 mg/day intravenous for 8 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 0
Study: 23954450

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy
Number of subjects: 12816
Study: 20938317

Group type: EXPERIMENTAL
Intervention: 2-week injury prevention course
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (standard education)
Number of subjects: 76
Study: 18262663

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine D3 receptor antagonism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New compounds targeting corticotropin‐releasing factor signalling and the endocannabinoid system
Number of subjects: 0
Study: 16603599

Group type: EXPERIMENTAL
Intervention: DCb (docetaxel 75 mg/m(2), carboplatin AUC 6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MIC/MVP (mitomycin 6 mg/m(2), ifosfamide 3 g/m(2) and cisplatin 50 mg/m(2) or mitomycin 6 mg/m(2), vinblastine 6 mg/m(2) and cisplatin 50 mg/m(2))
Number of subjects: 0
Study: 12535320

Group type: EXPERIMENTAL
Intervention: Physical class-based exercises for 8 months, 1 session of 60 min/week for 65 and 85 year-olds; 2 sessions/week for 75 year-olds.
Number of subjects: 3
Study: 11008086

Group type: EXPERIMENTAL
Intervention: Intervention group (school-based program including reproductive health classes, the Postponing Sexual Involvement Curriculum, health risk screening, and booster activities)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 582

Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 582
Study: 8902379

Group type: EXPERIMENTAL
Intervention: Supernormal DO2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal DO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regional assessment (gastric tonometer measurement of gastric mucosal PCO2 and pH)
Number of subjects: 0
Study: 1450706

Group type: EXPERIMENTAL
Intervention: Recombinant alpha interferon (IFN, 3 MU daily for 10 days followed by 3 MU twice/week for 3 months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 55
Study: 6377983

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (IT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no IT)
Number of subjects: 87
Study: 31570394

Group type: EXPERIMENTAL
Intervention: AT-527 600 mg once daily for seven days
Number of subjects: 0